Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
NMTC1
MCID: THY109
MIFTS: 55

Thyroid Cancer, Nonmedullary, 1 (NMTC1)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Thyroid Cancer, Nonmedullary, 1

About this section

MalaCards integrated aliases for Thyroid Cancer, Nonmedullary, 1:

Name: Thyroid Cancer, Nonmedullary, 1 57
Papillary Thyroid Carcinoma 20 29 6 17 71
Familial Nonmedullary Thyroid Cancer, Papillary 57 20 73
Nonmedullary Thyroid Carcinoma, Papillary 57 20 73
Nonmedullary Thyroid Carcinoma 1 29 6
Non-Medullary Thyroid Carcinoma 73 71
Papillary Carcinoma of Thyroid 57 73
Thyroid Carcinoma, Papillary 74 13
Nmtc1 57 73
Pact 57 73
Papillary Carcinoma of Thyroid; Pact; Ptc; Tpc 57
Familial Nonmedullary Thyroid Gland Carcinoma 71
Familial Non-Medullary Thyroid Cancer 73
Cancer, Thyroid, Nonmedullary, Type 1 39
Thyroid Carcinoma, Nonmedullary 1 71
Thyroid Cancer, Non-Medullary, 1 73
Nonmedullary Thyroid Carcinoma 73
Cancer, Thyroid, Nonmedullary 39
Thyroid Papillary Carcinoma 54
Papillary Thyroid Cancer 54
Fnmtc 73
Nmtc 73
Ptc 73
Tpc 73

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
autosomal dominant


HPO:

31
thyroid cancer, nonmedullary, 1:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM® 57 188550
OMIM Phenotypic Series 57 PS188550
MeSH 44 D013964
SNOMED-CT via HPO 68 255029007 263681008 3716002
UMLS 71 C0238463 C1853488 C3501843 more
Sources

Summaries for Thyroid Cancer, Nonmedullary, 1

About this section
OMIM® : 57 Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95% of all thyroid cancer cases. The remaining cancers originate from parafollicular cells (medullary thyroid cancer, MTC; 155240). NMTC is classified into 4 groups: papillary, follicular (188470), Hurthle cell (607464), and anaplastic. Approximately 5% of NMTC is hereditary, occurring as a component of a familial cancer syndrome (e.g., familial adenomatous polyposis, 175100; Carney complex, 160980) or as a primary feature (familial NMTC or FNMTC). Papillary thyroid cancer (PTC) is the most common histologic subtype of FNMTC, accounting for approximately 85% of cases (summary by Vriens et al., 2009). PTC is characterized by distinctive nuclear alterations including pseudoinclusions, grooves, and chromatin clearing. PTCs smaller than 1 cm are referred to as papillary microcarcinomas. These tumors have been identified in up to 35% of individuals at autopsy, suggesting that they may be extremely common although rarely clinically relevant. PTC can also be multifocal but is typically slow-growing with a tendency to spread to lymph nodes and usually has an excellent prognosis (summary by Bonora et al., 2010). (188550) (Updated 05-Mar-2021)

MalaCards based summary : Thyroid Cancer, Nonmedullary, 1, also known as papillary thyroid carcinoma, is related to papillary thyroid microcarcinoma and struma ovarii. An important gene associated with Thyroid Cancer, Nonmedullary, 1 is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Aztreonam and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and breast, and related phenotypes are goiter and papillary thyroid carcinoma

GARD : 20 Papillary thyroid carcinoma is a form of cancer that occurs due to abnormal and uncontrolled cell growth of certain cells (follicular cells) of the thyroid. Many people with papillary thyroid carcinoma have no signs or symptoms of the condition. When present, symptoms may include a small lump at the base of the neck, hoarseness, difficulty swallowing, trouble breathing, and pain in the neck or throat. Although people of all ages may be diagnosed with the condition, women between ages 30 and 50 are most commonly affected. The cause of papillary thyroid carcinoma is currently unknown. Risks for developing thyroid cancer include a history of high-dose external radiation treatments to the neck and radiation exposure during nuclear plant disasters. The best treatment options depend on many factors, but may include surgery, radiation therapy (including radioactive iodine therapy), chemotherapy and thyroid hormone therapy.

UniProtKB/Swiss-Prot : 73 Thyroid cancer, non-medullary, 1: A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

Wikipedia : 74 Papillary thyroid cancer or papillary thyroid carcinoma is the most common type of thyroid cancer,... more...

Sources

Related Diseases for Thyroid Cancer, Nonmedullary, 1

About this section

Diseases in the Familial Nonmedullary Thyroid Carcinoma family:

Thyroid Cancer, Nonmedullary, 2 Thyroid Cancer, Nonmedullary, 1
Thyroid Cancer, Nonmedullary, 3 Thyroid Cancer, Nonmedullary, 4
Thyroid Cancer, Nonmedullary, 5

Diseases related to Thyroid Cancer, Nonmedullary, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 728)
# Related Disease Score Top Affiliating Genes
1 papillary thyroid microcarcinoma 31.7 NKX2-1 BRAF
2 struma ovarii 31.5 NKX2-1 BRAF
3 thyroid gland disease 31.5 NKX2-1 MIR222 MIR221
4 thyroid gland anaplastic carcinoma 31.4 NKX2-1 MIR222 BRAF
5 thyroid gland papillary carcinoma 30.9 GAS8-AS1 BRAF
6 differentiated thyroid carcinoma 30.8 NKX2-1 GAS8-AS1 BRAF
7 benign struma ovarii 30.6 NKX2-1 BRAF
8 follicular adenoma 30.6 NKX2-1 MIR222 MIR221 BRAF
9 retinitis pigmentosa 11 30.6 MIR146A HOTAIR CCND2-AS1
10 lung cancer susceptibility 3 30.5 NKX2-1 LINC-ROR HOTAIR H19 BRAF
11 thyroid carcinoma 30.5 NKX2-1 HOTAIR H19 BRAF
12 diffuse large b-cell lymphoma 30.4 MIR222 MIR221 HULC HOTAIR
13 melanoma 30.4 MIR222 MIR221 LINC-ROR HOTAIR H19 BRAF
14 thyroid gland follicular carcinoma 30.4 NKX2-1 MIR222 MIR221 BRAF
15 thyroid gland cancer 30.4 NKX2-1 MIR222 MIR221 BRAF
16 osteogenic sarcoma 30.2 HULC HOTTIP HOTAIR H19 BANCR
17 glioblastoma 30.2 MIR222 MIR221 HOTAIR H19 BRAF
18 myeloma, multiple 30.1 NKX2-1 HOTAIR H19 BRAF
19 oral squamous cell carcinoma 30.0 MIR221 MIR146A HOTAIR H19
20 ovarian epithelial cancer 29.9 HULC HOTAIR H19
21 leukemia, chronic myeloid 29.9 HULC HOTAIR H19 BRAF
22 renal cell carcinoma, nonpapillary 29.9 NKX2-1 MIR221 LINC-ROR HOTAIR H19 BRAF
23 pancreatic ductal adenocarcinoma 29.8 MIR222 MIR221 MIR146A HOTTIP HOTAIR H19
24 high grade glioma 29.7 LINC-ROR HULC HOTTIP HOTAIR H19
25 bladder cancer 29.7 MIR222 MIR221 HULC HOTAIR H19 BRAF
26 gallbladder cancer 29.6 LINC-ROR HOTAIR H19
27 squamous cell carcinoma, head and neck 29.6 MIR221 HOTAIR H19 BRAF
28 esophageal cancer 29.5 MIR146A LINC-ROR HULC HOTTIP HOTAIR H19
29 glioma 29.5 MIR222 MIR221 HULC HOTTIP HOTAIR H19
30 nasopharyngeal carcinoma 29.2 LINC-ROR HULC HOTAIR H19
31 gastric cancer 29.2 MIR222 MIR221 MIR146A LINC-ROR HULC HOTTIP
32 pancreatic cancer 29.0 MIR222 MIR221 MIR146A LINC-ROR HULC HOTTIP
33 thyroid cancer, nonmedullary, 3 11.5
34 thyroid carcinoma, papillary, with papillary renal neoplasia 11.5
35 multicentric papillary thyroid carcinoma 11.4
36 thiourea tasting 11.1
37 thyroid cancer, nonmedullary, 2 10.9
38 thyroid cancer, nonmedullary, 4 10.9
39 thyroid cancer, nonmedullary, 5 10.9
40 papillary carcinoma 10.9
41 hypoparathyroidism 10.8
42 hashimoto thyroiditis 10.8
43 hyperparathyroidism 10.7
44 hyperthyroidism 10.7
45 primary hyperparathyroidism 10.6
46 teratoma 10.5
47 lymphoma 10.5
48 multiple endocrine neoplasia 10.5
49 pheochromocytoma 10.5
50 adrenal gland pheochromocytoma 10.5

Graphical network of the top 20 diseases related to Thyroid Cancer, Nonmedullary, 1:



Diseases related to Thyroid Cancer, Nonmedullary, 1
Sources

Symptoms & Phenotypes for Thyroid Cancer, Nonmedullary, 1

About this section

Human phenotypes related to Thyroid Cancer, Nonmedullary, 1:

31
# Description HPO Frequency HPO Source Accession
1 goiter 31 HP:0000853
2 papillary thyroid carcinoma 31 HP:0002895
3 non-medullary thyroid carcinoma 31 HP:0040198

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Neoplasia:
nonmedullary thyroid carcinoma (papillary)
goiter, multinodular

Clinical features from OMIM®:

188550 (Updated 05-Mar-2021)

Sources

Drugs & Therapeutics for Thyroid Cancer, Nonmedullary, 1

About this section

Drugs for Thyroid Cancer, Nonmedullary, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aztreonam Approved Phase 4 78110-38-0 5362041 5742832
2 Anti-Infective Agents Phase 4
3 Antibiotics, Antitubercular Phase 4
4 Anti-Bacterial Agents Phase 4
5
Iodine Approved, Investigational Phase 2, Phase 3 7553-56-2 807
6
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
7
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
8
Zoledronic Acid Approved Phase 3 118072-93-8 68740
9
Prazosin Approved Phase 3 19216-56-9 4893
10
Cadexomer iodine Experimental Phase 2, Phase 3 94820-09-4
11 Hormones Phase 3
12 Tubulin Modulators Phase 3
13 Antimitotic Agents Phase 3
14 Neurotransmitter Agents Phase 3
15 Adrenergic alpha-1 Receptor Antagonists Phase 3
16 Adrenergic alpha-Antagonists Phase 3
17 Adrenergic Antagonists Phase 3
18 Antihypertensive Agents Phase 3
19 Adrenergic Agents Phase 3
20
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
21
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
22
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
23
Calcium carbonate Approved, Investigational Phase 2 471-34-1
24
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
25
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
26
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
27
Durvalumab Approved, Investigational Phase 2 1428935-60-7
28
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
29
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
30
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
31
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
32
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
33
Alfacalcidol Approved, Nutraceutical Phase 2 41294-56-8 5282181
34
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
35
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
36
Tremelimumab Investigational Phase 2 745013-59-6
37 Angiogenesis Inhibitors Phase 2
38 Protein Kinase Inhibitors Phase 2
39 Nutrients Phase 2
40 Micronutrients Phase 2
41 Vitamin D2 Phase 2
42 Antacids Phase 2
43 Gastrointestinal Agents Phase 2
44 Ergocalciferols Phase 2
45 Vitamins Phase 2
46 Trace Elements Phase 2
47 Anti-Ulcer Agents Phase 2
48 Calcium, Dietary Phase 2
49 Calciferol Phase 2
50 Hydroxycholecalciferols Phase 2

Interventional clinical trials:

(show top 50) (show all 123)
# Name Status NCT ID Phase Drugs
1 IN-PACT CORO INtimal hyPerplasia evAluated by oCT in de Novo COROnary Lesions Treated by Drug-eluting Balloon and Bare-metal Stent Unknown status NCT01057563 Phase 4
2 A-PACT: The Use of Inhaled Aztreonam to Eliminate or Decrease the Bacterial Burden of Pseudomonas Aeruginosa in Children With a Tracheostomy Tube. Terminated NCT03158116 Phase 4 Inhaled Aztreonam
3 Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
4 Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial) Completed NCT01083550 Phase 2, Phase 3
5 Pediatric Asthma Controller Trial (PACT) Completed NCT00272506 Phase 3 inhaled corticosteroid;long-acting beta2-agonist
6 Non-small Cell Lung Cancer Study US75 (Z-PACT) Completed NCT00086268 Phase 3 zoledronic acid;Taxotere;Carboplatin
7 CSP #563 - Prazosin and Combat Trauma PTSD (PACT) Completed NCT00532493 Phase 3 prazosin
8 Models of Primary Osteoporosis Screening in Male Veterans Active, not recruiting NCT04079868 Phase 2, Phase 3
9 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
10 Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements Completed NCT00559949 Phase 2 Selumetinib
11 Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma Completed NCT00887107 Phase 2 Sorafenib (nexavar)
12 A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma Completed NCT00104871 Phase 2 Bortezomib
13 Phase 2 Study of Routine Oral Calcium and Vitamine D Supplements to Prevent Hypocalcemia After Total Thyroidectomy in Papillary Thyroid Carcinoma Patients Completed NCT00630214 Phase 2
14 A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma Completed NCT01502410 Phase 2 sorafenib tosylate
15 Thyroid Gland Removal With or Without Central Lymph Node Dissection in Treating Patients With Node Negative Thyroid Cancer Completed NCT02138214 Phase 2
16 Randomized Controlled Trial of Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in Patients With Low-risk Papillary Thyroid Cancer Completed NCT02408887 Phase 2
17 An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine Completed NCT01286753 Phase 2 Vemurafenib
18 Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine Completed NCT00085293 Phase 2 Decitabine
19 The Participant Agreement for Contact Tracing (PACT) Study: Enhancing Partner Notification Services. Completed NCT00207493 Phase 1, Phase 2
20 A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial Recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
21 Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy Recruiting NCT02593175 Phase 2 Carboplatin;Paclitaxel
22 A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer Recruiting NCT02876107 Phase 2 Carboplatin;Paclitaxel
23 Radiofrequency Ablation for Low Risk Papillary Thyroid Cancer: A Pilot Study Unknown status NCT00103155 Phase 1
24 A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors Completed NCT01100619 Phase 1 rosiglitazone;XL184
25 Detection of Thyroid Cancer and Central Lymph Node Metastases Using EMI-137 Enhanced Molecular Fluorescent Guided Imaging: a Multicentre Feasibility and Completed NCT03470259 Phase 1 IV adminstration of EMI-137
26 A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodium Iodide Symporter Function and Sensitivity to Radioiodine Treatment in Metastatic Thyroid Cancer Patients Recruiting NCT03469011 Phase 1 Imatinib Oral Tablet
27 A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT) Active, not recruiting NCT02791334 Phase 1 LY3300054;Ramucirumab;Abemaciclib;Merestinib;LY3321367
28 Phase 1 Study of X-PACT (X-ray Psoralen Activated Cancer Therapy) for Intra-tumoral Injection in Patients With Advanced Head and Neck Cancer, Breast Cancer, Soft Tissue Sarcoma or Melanoma Not yet recruiting NCT04389281 Phase 1
29 Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma Unknown status NCT01417442 Early Phase 1
30 99mTechnetium-MIBI SPECT-CT for Pre-operative Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma; A Pilot Study Unknown status NCT00984191
31 Comparative Analysis Between A Bipolar Vessel Sealing and Cutting Device and the Tie and Suture Technique in Thyroidectomy: A Two Institution Randomized Clinical Trial Unknown status NCT02140476
32 Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated With the Harmonic ACE® Scalpel and LigaSure Preciseâ„¢ Instrument During Conventional Thyroidectomy: A Single-blind Prospective Randomized Controlled Trial Unknown status NCT01565486
33 Differences Protein Expression in Papillary Thyroid Carcinoma Unknown status NCT02814032
34 Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma Unknown status NCT02648399
35 Clinical Investigations on Cytokin-Gradients in Hypo/Euthyroid Patients. Evaluation of Expression of Different Pro-and Anti-Inflammatory Cyto-/Chemokines in Skin Wounds After Surgery of Benign Goitres (Struma Multinodosa) or Malignant Diseases of Thyroid Gland (Papillary Thyroid Carcinoma) in Correlation to the Status of Wound Healing of the Neck Wound Unknown status NCT00929318
36 Effectiveness and Cost-effectiveness of Interdisciplinary Teamwork in Medical Emergencies: The PAtient-Centred Team (PACT) Service Model. Effect and Cost Effectiveness Evaluation Unknown status NCT02541474
37 Peer-lead and Telemedicine Activated Care (PACT) in Diabetes Prevention and Management Unknown status NCT01307137
38 The PACT Trial - PAtient Centered Telerehabilitation: Effectiveness of Software-supported and Traditional Mirror Therapy in Patients With Phantom Limb Pain Following Lower Limb Amputation: Design of a Randomized Controlled Trial. Unknown status NCT02076490
39 Falls Prevention Through Physical And Cognitive Training (Falls PACT) in Older Adults With Mild Cognitive Impairment: A Randomised Controlled Trial Unknown status NCT03167840
40 Prophylactic Central Neck Dissection for Papillary Thyroid Cancer Completed NCT01510002
41 Using Circulating Biomarkers to Identify Thyroid Cancer From the Patients With Thyroid Nodules Completed NCT04594720
42 Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study Completed NCT01927887 Ferumoxytol
43 Association Between BRAF V600E and Redifferentiation Therapy in Patients With Radioiodine-refractory Papillary Thyroid Cancer Completed NCT03363347 Redifferentiation with retinoid acid
44 Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy Completed NCT02768753
45 Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy Completed NCT01354639
46 Immunohistochemical Detection of the BRAFV600E Mutation on Cytological Specimen in PTC Completed NCT02561533
47 A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy : Postoperative Body Image Change and Cosmetic Satisfaction Completed NCT01311089
48 Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 Completed NCT01534897 GSK2118436
49 APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS. Completed NCT02323724
50 The Effectiveness of Prophylactic Selective Lateral Neck Dissection in Papillary Thyroid Carcinoma Patients With Central Neck Metastasis Completed NCT01103557

Search NIH Clinical Center for Thyroid Cancer, Nonmedullary, 1

Sources

Genetic Tests for Thyroid Cancer, Nonmedullary, 1

About this section

Genetic tests related to Thyroid Cancer, Nonmedullary, 1:

# Genetic test Affiliating Genes
1 Papillary Thyroid Carcinoma 29
2 Nonmedullary Thyroid Carcinoma 1 29 NKX2-1
Sources

Anatomical Context for Thyroid Cancer, Nonmedullary, 1

About this section

MalaCards organs/tissues related to Thyroid Cancer, Nonmedullary, 1:

40
Thyroid, Lymph Node, Breast, Lung, Bone, Endothelial, Brain
Sources

Publications for Thyroid Cancer, Nonmedullary, 1

About this section

Articles related to Thyroid Cancer, Nonmedullary, 1:

(show top 50) (show all 8045)
# Title Authors PMID Year
1
A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma. 61 6 54 57
19176457 2009
2
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. 61 6 57 54
12670889 2003
3
Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. 57 6 54
15181070 2004
4
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. 54 6 61
17785355 2007
5
Comparison of the breakpoint regions of ELE1 and RET genes involved in the generation of RET/PTC3 oncogene in sporadic and in radiation-associated papillary thyroid carcinomas. 57 54 61
9192845 1997
6
Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. 54 61 57
1569189 1992
7
The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. 61 57
22586128 2012
8
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. 54 57
18000091 2008
9
Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings. 61 57
17956956 2008
10
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. 54 6
17488796 2007
11
Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. 6 54
16772349 2006
12
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. 54 6
16174717 2005
13
High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. 6 54
15998781 2005
14
Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. 54 6
15687339 2005
15
Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis. 61 57
15546898 2005
16
Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. 54 6
15356022 2004
17
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. 6 54
15126572 2004
18
BRAF T1796A transversion mutation in various thyroid neoplasms. 6 54
15001635 2004
19
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. 6 54
14602780 2003
20
Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. 54 57
12970315 2003
21
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). 61 57
12679489 2003
22
Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma. 61 57
12574236 2003
23
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. 57 61
11861385 2002
24
Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements. 57 61
11747322 2001
25
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. 54 57
11443191 2001
26
Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. 61 57
11158026 2001
27
Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia. 57 61
10946873 2000
28
RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma. 57 61
10980597 2000
29
The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. 61 57
10720057 2000
30
Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer. 54 57
10487693 1999
31
Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. 61 57
9814501 1998
32
Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. 57 54
8187085 1994
33
Familial occurrence of papillary thyroid carcinoma. 57 61
7214311 1980
34
Codon-specific translation reprogramming promotes resistance to targeted therapy. 6
29925953 2018
35
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. 6
28854169 2017
36
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. 6
25079330 2014
37
Copper is required for oncogenic BRAF signalling and tumorigenesis. 6
24717435 2014
38
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. 6
24670642 2014
39
Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. 6
24512911 2014
40
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. 6
23685455 2013
41
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. 6
23302800 2013
42
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. 6
22281684 2012
43
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). 6
22113612 2011
44
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 6
21107320 2010
45
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. 6
21107323 2010
46
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. 6
20823850 2010
47
Inhibition of mutated, activated BRAF in metastatic melanoma. 6
20818844 2010
48
The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl. 57
20350937 2010
49
Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies. 57
20628519 2010
50
miRNA expression in a human papillary thyroid carcinoma cell line varies with invasiveness. 47 61
19851034 2010
Sources

Variations for Thyroid Cancer, Nonmedullary, 1

About this section

ClinVar genetic disease variations for Thyroid Cancer, Nonmedullary, 1:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NKX2-1 NM_001079668.3(NKX2-1):c.1106C>T (p.Ala369Val) SNV Pathogenic 487553 rs537209983 14:36986583-36986583 14:36517378-36517378
2 BRAF NM_001374258.1(BRAF):c.1919T>A (p.Val640Glu) SNV Pathogenic 13961 rs113488022 7:140453136-140453136 7:140753336-140753336
3 LIG4 NM_206937.2(LIG4):c.1673A>C (p.Gln558Pro) SNV Likely pathogenic 620632 rs751409106 13:108861944-108861944 13:108209596-108209596
4 NKX2-1 NM_001079668.3(NKX2-1):c.463+4A>G SNV Uncertain significance 930341 14:36988186-36988186 14:36518981-36518981
5 PALB2 NM_024675.3(PALB2):c.2147A>G (p.Asn716Ser) SNV Uncertain significance 232654 rs148335539 16:23641328-23641328 16:23630007-23630007
6 RUNX1 NM_001754.5(RUNX1):c.749G>A SNV Uncertain significance 239055 rs771614642 21:36206763-36206763 21:34834466-34834466
7 PCM1 NM_006197.4(PCM1):c.2935C>T (p.Gln979Ter) SNV Uncertain significance 225430 rs1085307084 8:17823587-17823587 8:17966078-17966078

UniProtKB/Swiss-Prot genetic disease variations for Thyroid Cancer, Nonmedullary, 1:

73
# Symbol AA change Variation ID SNP ID
1 NKX2-1 p.Ala339Val VAR_075769 rs537209983

Copy number variations for Thyroid Cancer, Nonmedullary, 1 from CNVD:

7 (show all 16)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13343 1 1 124300000 Chromosomal rearrangement Papillary thyroid carcinoma
2 13804 1 1 60900000 Chromosomal rearrangement Papillary thyroid carcinoma
3 19995 1 152394403 152431233 Translate TPM3 Papillary thyroid carcinoma
4 42899 10 42100000 53300000 Chromosomal rearrangement Papillary thyroid carcinoma
5 44673 10 61218526 61336824 Translate CCDC6 Papillary thyroid carcinoma
6 91970 15 37900000 47600000 Copy number FGF7 Papillary thyroid carcinoma
7 95418 15 76100000 86900000 Copy number AKAP13 Papillary thyroid carcinoma
8 96732 15 92330402 92376057 Translate GOLGA5 Papillary thyroid carcinoma
9 106730 17 1 11200000 Copy number USP6 Papillary thyroid carcinoma
10 140387 2 197100000 209100000 Copy number TRAK2 Papillary thyroid carcinoma
11 148729 2 83700000 91000000 Amplification TMSB10 Papillary thyroid carcinoma
12 166063 3 1 14700000 Chromosomal rearrangement Papillary thyroid carcinoma
13 166395 3 101910849 101950501 Translate TFG Papillary thyroid carcinoma
14 194280 5 139000000 143100000 Copy number EIF4EBP3 Papillary thyroid carcinoma
15 219438 7 126900000 158821424 Chromosomal rearrangement Papillary thyroid carcinoma
16 232143 8 112100000 146364022 Amplification Papillary thyroid cancer
Sources

Expression for Thyroid Cancer, Nonmedullary, 1

About this section
Search GEO for disease gene expression data for Thyroid Cancer, Nonmedullary, 1.
Sources

Pathways for Thyroid Cancer, Nonmedullary, 1

About this section

Pathways related to Thyroid Cancer, Nonmedullary, 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
LncRNA-mediated mechanisms of therapeutic resistance 1
9.7 LINC-ROR HOTAIR
Sources

GO Terms for Thyroid Cancer, Nonmedullary, 1

About this section

Biological processes related to Thyroid Cancer, Nonmedullary, 1 according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.78 MIR222 MIR221 BRAF APELA
2 negative regulation of inflammatory response GO:0050728 9.7 MIR222 MIR221 MIR146A
3 miRNA mediated inhibition of translation GO:0035278 9.69 MIR222 MIR221 MIR146A
4 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.61 MIR222 MIR221 MIR146A
5 endoderm development GO:0007492 9.56 NKX2-1 APELA
6 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.55 MIR146A APELA
7 thyroid gland development GO:0030878 9.54 NKX2-1 BRAF
8 negative regulation by host of viral genome replication GO:0044828 9.49 MIR222 MIR221
9 negative regulation of interleukin-21 production GO:0032705 9.46 MIR222 MIR221
10 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.4 MIR222 MIR221
11 positive regulation of Schwann cell migration GO:1900149 9.37 MIR222 MIR221
12 negative regulation of cell adhesion molecule production GO:0060354 9.33 MIR222 MIR221 MIR146A
13 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.32 MIR222 MIR221
14 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.26 MIR222 MIR221
15 positive regulation of axon regeneration GO:0048680 9.13 MIR222 MIR221 BRAF
16 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 8.8 MIR222 MIR221 MIR146A
Sources

Sources for Thyroid Cancer, Nonmedullary, 1

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....